1. Indications and Usage
\nReduction in Risk of Stroke and Systemic Embolism (SE) in Nonvalvular Atrial Fibrillation (NVAF): To reduce the risk of stroke and SE in patients with NVAF.
\nTreatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): For the treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for 5-10 days.
\n2. Dosage and Administration
\nRecommended Dose:
\nNVAF: 60 mg once daily. Reduce to 30 mg once daily for patients with CrCL 15-50 mL\/min, body weight \u226460 kg, or those using specific P-gp inhibitors. Do not use if CrCL >95 mL\/min due to reduced efficacy.
\nDVT\/PE: 60 mg once daily. Reduce to 30 mg once daily for patients with CrCL 15-50 mL\/min, body weight \u226460 kg, or those using specific P-gp inhibitors.
\nAdministration: Oral administration. Can be taken with or without food.
\nMissed Dose: Take as soon as possible on the same day. If the next dose is due within 6 hours, skip the missed dose. Do not take two doses on the same day.
\n3. Mechanism of Action
\nDirect Factor Xa Inhibitor: Edoxaban is an oral, direct Factor Xa inhibitor.
\nPathway: It binds reversibly and selectively to the active site of Factor Xa, blocking the conversion of prothrombin to thrombin. This prevents the formation of fibrin clots, thereby reducing the risk of thrombosis.
\n4. Safety and Warnings
\nBleeding Risk: Can cause serious, potentially fatal bleeding. Discontinue in cases of active pathological bleeding.
\nSpinal\/Epidural Anesthesia: Patients undergoing spinal puncture or epidural anesthesia are at risk of spinal or epidural hematomas, which can result in long-term or permanent paralysis.
\nContraindications:
\nActive pathological bleeding.
\nSevere hypersensitivity to edoxaban.
\nRenal Impairment: Not recommended for patients with CrCL >95 mL\/min (NVAF only) or severe renal impairment (CrCL <15 mL\/min) \/ end-stage renal disease.
\n5. Adverse Reactions
\nNVAF: The most common adverse reaction (\u22655%) is bleeding. Anemia is also common.
\nDVT\/PE: Common adverse reactions (\u22651%) include bleeding, rash, abnormal liver function tests, and anemia.
\n6. Drug Interactions
\nP-gp Inhibitors: Concomitant use with P-gp inhibitors (e.g., cyclosporine, dronedarone, erythromycin, ketoconazole) requires dose reduction to 30 mg.
\nP-gp Inducers: Avoid concomitant use with strong P-gp inducers (e.g., rifampin) as they may significantly decrease edoxaban exposure.
\nAnticoagulants\/Antiplatelets: Concomitant use with other anticoagulants (e.g., heparin) or antiplatelet agents (e.g., aspirin, clopidogrel) increases bleeding risk.
\n7. Pharmaceutical Information
\nChemical Name:N\u00b9-(5-chloropyridin-2-yl)-N\u00b2-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-carbonyl)amino]cyclohexyl]oxalamide<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u91cc\u5148\u5b89\u00ae\uff08Lixiana\u00ae\uff09
\nGeneric Name: Edoxaban
\nStrength: 60 mg per film-coated tablet, 7 film-coated tablets per box
\nManufacturer: Daiichi Sankyo Europe GmbH (Germany)
\nMarketing Authorization Holder: Daiichi Sankyo Co., Ltd.\uff1bDomestic Responsible Party: \u7b2c\u4e00\u4e09\u5171\u5236\u836f\uff08\u4e0a\u6d77\uff09\u6709\u9650\u516c\u53f8
\nApproval Date in China: June 29, 2018
\nRegistration Number:\u56fd\u836f\u51c6\u5b57 HJ20180099
\nStorage: No special storage requirements; store in the original blister pack, avoid high temperature and humidity, and keep out of sight and reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Edoxaban\uff08Lixiana\uff09<\/p>\n","protected":false},"featured_media":3047,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-3046","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n